Published in Gene Therapy Weekly, March 25th, 2004
According to a study from the United States, "liver injury induced by ischemia/reperfusion (I/R) is the prime factor in delayed or loss graft function following transplantation. CD4+ T lymphocytes are key cellular mediators of antigen-independent inflammatory response triggered by I/R. We attempted to modulate rat liver I/R injury by targeted gene therapy with CD401g, which blocks the CD40-CD154 costimulation pathway."
"One hundred percent of Ad-CD401g-pretreated orthotopic liver transplants (OLTs) subjected to 24 hours of cold (4 degree C) ischemia survived >14 days (vs. 50%...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.